更新于：2024-11-01

Chronic peptic ulcer

慢性消化性溃疡

更新于：2024-11-01

基本信息

别名

Chronic peptic ulcer、Chronic peptic ulcer (disorder)、chronic peptic ulcer

+ [4]

简介-

关联

项与慢性消化性溃疡相关的药物

Pantoprazole Sodium Hydrate

泮托拉唑钠

靶点

Proton pump

作用机制

质子泵抑制剂

在研机构

Takeda Pharmaceuticals Australia Pty Ltd. [+9]

原研机构

Takeda Pharmaceutical Co., Ltd.

在研适应症

糜烂性食管炎 [+8]

非在研适应症

慢性消化性溃疡 [+6]

最高研发阶段批准上市

首次获批国家/地区

德国

首次获批日期1994-01-01

项与慢性消化性溃疡相关的临床试验

IRCT20091114002709N63 / RecruitingN/AIIT

The effect of beginning time of oral feeding on the length of hospitalization, risk of rebleeding and nutritional status of patients with upper gastrointestinal bleeding caused by peptic ulcers and erosive diseases

开始日期2023-08-13

申办/合作机构

Iran University of Medical Sciences & Health Services

CTR20222536 / CompletedN/A

奥美拉唑镁肠溶片人体生物等效性研究（空腹）

主要目的：本试验旨在研究单次空腹口服重庆莱美药业股份有限公司研制、生产的奥美拉唑镁肠溶片（20 mg）的药代动力学特征；以AstraZeneca AB生产的奥美拉唑镁肠溶片（洛赛克MUPS®，20 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。次要目的：观察受试制剂奥美拉唑镁肠溶片和参比制剂奥美拉唑镁肠溶片（洛赛克MUPS®）在健康受试者中的安全性。

开始日期2022-10-08

申办/合作机构

重庆莱美药业股份有限公司

CTR20221107 / CompletedN/A

奥美拉唑镁肠溶片人体生物等效性研究（餐后试验）

主要目的：本试验旨在研究单次餐后口服重庆莱美药业股份有限公司研制、生产的奥美拉唑镁肠溶片（20 mg）的药代动力学特征；以AstraZeneca AB生产的奥美拉唑镁肠溶片（洛赛克MUPS®，20 mg）为参比制剂，比较两制剂中药动学参数Cmax、AUC0-t、AUC0-∞，评价两制剂的人体生物等效性。次要目的：观察受试制剂奥美拉唑镁肠溶片和参比制剂奥美拉唑镁肠溶片（洛赛克MUPS®）在健康受试者中的安全性。

开始日期2022-05-27

申办/合作机构

重庆莱美药业股份有限公司

100 项与慢性消化性溃疡相关的临床结果

登录后查看更多信息

100 项与慢性消化性溃疡相关的转化医学

登录后查看更多信息

0 项与慢性消化性溃疡相关的专利（医药）

登录后查看更多信息

440

项与慢性消化性溃疡相关的文献（医药）

2024-02-01·BMJ Case Reports

Choledocho-gastric fistula due to chronic peptic ulcer with gastric outlet obstruction and pneumobilia

Article

作者: Ajmal, Imran Tariq ; Rino, Roshan V ; Anand, Priyanka ; Muralidhar, Venkiteswaran

2024-01-01·Stem Cells International

Mesenchymal Stem Cells Accelerate Recovery of Acetic Acid‐Induced Chronic Gastric Ulcer by Regulating Ekt/Akt/TRIM29 Axis

Article

作者: Fan, Zhibin ; Sui, Jianliang ; Jia, Ruikang ; Zhao, Feiyue ; Wang, Menglei ; Liu, Qichao ; Liu, Huiyun

Chronic gastric ulcer (CGU), a prevalent digestive disease, has a high incidence and is seriously harmful to human health. Mesenchymal stem cells (MSCs) have been proven to have beneficial therapeutic effects in many human diseases. Here, a CGU model induced by acetic acid in mice was used to evaluate the repair effects and potential mechanism of human umbilical cord‐derived MSCs (hUC‐MSCs) and hUC‐MSCs derived conditioned medium (hUC‐MSC‐CM). We found that hUC‐MSCs and hUC‐MSC‐CM treatment significantly repaired morphological characteristics of CGU, improved proliferation and decreased apoptosis of gastric cells, and promoted the generation of new blood vessels in granulation tissues. In addition, we could detect the homing of MSCs in gastric tissue, and MSCs may differentiate into Lgr5‐positive cells. As well as this, in vitro experiments showed that hUC‐MSC‐CM could promote cell proliferation, stimulate cell cycle progression, and reduce the incidence of apoptosis. The transcriptome of cells and the iTRAQ proteome of gastric tissues suggest that MSCs may play a therapeutic role by increasing the expression of TRIM29. Additionally, it was found that knocking down TRIM29 significantly decreased the ameliorative effects of hUC‐MSC‐CM on cell apoptosis. As a result of further molecular experiments, it was found that TRIM29 is capable of phosphorylating Erk/Akt in specific cell type. As a whole, it appears that hUC‐MSCs can be an effective therapeutic approach for promoting gastric ulcer healing and may exert therapeutic effects in the form of paracrine and differentiation into gastric cells.

2023-09-16·Lancet (London, England)1区 · 医学

Gastric outlet obstruction secondary to chronic peptic ulcer disease.

1区 · 医学

Article

作者: Sharbatdaran, Arman ; Sakla, Nicole